Changing the Course of Lyme Disease

About Us

FlightpathTM Biosciences is a biotechnology company developing novel therapeutics for the treatment of tick-borne diseases


Based on results of a comprehensive high-throughput screen to identify a maximally-effective antiobiotic against Borrelia burgdorferi, Flightpath is developing an oral semisynthetic, broad-spectrum, bactericidal antibiotic (FP-101) for the treatment of acute and Post Treatment Lyme Disease (PTLD).

Flightpath has received both venture funding from private investors and philanthropic organizations.